16:37:14 EDT Fri 24 May 2024
Enter Symbol
or Name
USA
CA



TransCode Therapeutics: Invitation to The ThinkEquity Conference

2022-10-19 08:02 ET - News Release

Boston, Massachusetts--(Newsfile Corp. - October 19, 2022) - TransCode Therapeutics (NASDAQ: RNAZ), the RNA Oncology company committed to more effectively treating cancer using RNA therapeutics, will be participating in The ThinkEquity Conference, which will take place on October 26, 2022 at The Mandarin Oriental Hotel in New York.

Michael Dudley- CEO/ Co-Founder- will be presenting at 2:30 PM ET on October 26th. Interested parties can register to attend here. Members of the TransCode Therapeutics management will also be holding one-on-one investor meetings throughout the day.

The presentation will also be live-streamed at the following link.

About TransCode Therapeutics

TransCode is an RNA oncology company created on the belief that cancer can be effectively treated using RNA therapeutics. The Company hascreated a platform of drug candidates designed to target a variety of tumor types with the objective of significantly improving patient outcomes. TheCompany's lead therapeutic candidate, TTX-MC138, is focused on treating metastatic cancer, which is believed to cause approximately 90% of allcancer deaths totaling over nine million per year worldwide. The Company believes that TTX-MC138 has the potential to produce regression withoutrecurrence in a range of cancers, including breast, pancreatic, ovarian and colon cancer, glioblastomas and others. Two of the Company's other drugcandidates, TTX-siPDL1 and TTX-siLIN28B, focus on treating tumors by targeting PD-L1 and LIN28B, respectively. TransCode also has three canceragnosticprograms: TTX-RIGA, an RNA-based agonist of the retinoic acid-inducible gene I, or RIG-I, designed to drive an immune response in thetumor microenvironment; TTX-CRISPR, a CRISPR/Cas9-based therapy platform for the repair or elimination of cancer-causing genes inside tumorcells; and TTX-mRNA, an mRNA-based platform for the development of cancer vaccines designed to activate cytotoxic immune responses againsttumor cells.

About The ThinkEquity Conference

The ThinkEquity Conference will gather industry insiders, investors and leading executives from around the world on October 26th in New York. Attendees can expect a full day of company presentations, panel discussions, one-on-one investor meetings and more.

Featured sectors include AI/Big data technology, Biotechnology, EV/EV Infrastructure, Metals & Mining and Oil & Gas.

To register to attend The ThinkEquity Conference, please follow this link.

For further information:
Alan Freidman
VP Investor Relations
617-429-6033
alan.freidman@transcodetherapeutics.com

Source: TransCode Therapeutics

© 2024 Canjex Publishing Ltd. All rights reserved.